scholarly journals In Vitro Activity of API-1252, a Novel FabI Inhibitor, against Clinical Isolates of Staphylococcus aureus and Staphylococcus epidermidis

2007 ◽  
Vol 51 (4) ◽  
pp. 1580-1581 ◽  
Author(s):  
James A. Karlowsky ◽  
Nancy M. Laing ◽  
Nachum Kaplan ◽  
Daryl J. Hoban ◽  
George G. Zhanel ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Staphylococcus Epidermidis ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity

scholarly journals Determining Linezolid’s Baseline In Vitro Activity in Canada Using Gram-Positive Clinical Isolates Collected prior to Its National Release

2002 ◽  
Vol 46 (6) ◽  
pp. 1989-1992 ◽  
Author(s):  
James A. Karlowsky ◽  
Laurie J. Kelly ◽  
Ian A. Critchley ◽  
Mark E. Jones ◽  
Clyde Thornsberry ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Streptococcus Pneumoniae ◽  
Staphylococcus Epidermidis ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
Clinical Use ◽  
In Vitro Activity ◽  
Gram Positive ◽  
Future Studies

ABSTRACT All of the isolates of Staphylococcus aureus (n = 317), Enterococcus species (n = 315), Streptococcus pneumoniae (n = 282), and Staphylococcus epidermidis (n = 176) collected at 16 Canadian microbiology laboratories from October 2000 to April 2001 were susceptible to linezolid. Future studies will determine how linezolid clinical use in Canada affects its in vitro activity.

scholarly journals In Vitro Activity of Nemonoxacin, a Novel Nonfluorinated Quinolone, against 2,440 Clinical Isolates

2009 ◽  
Vol 53 (11) ◽  
pp. 4915-4920 ◽  
Author(s):  
Heather J. Adam ◽  
Nancy M. Laing ◽  
C. Richard King ◽  
Ben Lulashnyk ◽  
Daryl J. Hoban ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Staphylococcus Aureus ◽  
Pseudomonas Aeruginosa ◽  
Staphylococcus Epidermidis ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
Gram Negative ◽  
Gram Positive Cocci

ABSTRACT The in vitro activity of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, was tested against 2,440 clinical isolates. Nemonoxacin was at least fourfold more active than levofloxacin and moxifloxacin against most gram-positive cocci tested (shown by the following MIC90/range [μg/ml] values; community-associated methicillin [meticillin]-resistant Staphylococcus aureus, 0.5/0.015 to 2; Staphylococcus epidermidis, 0.5/0.015 to 4 for methicillin-susceptible staphylococci and 2/0.12 to 2 for methicillin-resistant staphylococci; Streptococcus pneumoniae, 0.015/≤0.008 to 0.25; Enterococcus faecalis, 1/0.03 to 128). Nemonoxacin activity against gram-negative bacilli was similar to levofloxacin and moxifloxacin (MIC90/range [μg/ml]; Escherichia coli, 32/≤0.015 to ≥512; Klebsiella pneumoniae, 2/≤0.015 to 128; K. oxytoca, 0.5/0.06 to 1; Proteus mirabilis, 16/0.25 to ≥512; Pseudomonas aeruginosa, 32/≤0.015 to ≥512; Acinetobacter baumannii, 1/0.12 to 16).

In Vitro Activity of Nadifloxacin against both Methicillin-Susceptible and -Resistant Clinical Isolates of Staphylococcus aureus from Patients with Skin Infections

Drugs ◽  
1995 ◽  
Vol 49 (Supplement 2) ◽  
pp. 230-232 ◽  
Author(s):  
S. Nishijima ◽  
S. Namura ◽  
H. Akamatsu ◽  
S. Kawai ◽  
Y. Asada ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
Skin Infections ◽  
In Vitro Activity

scholarly journals In vitro activity of minocycline combined with fosfomycin against clinical isolates of methicillin-resistant Staphylococcus aureus

2011 ◽  
Vol 64 (8) ◽  
pp. 559-562 ◽  
Author(s):  
Chunguang Sun ◽  
Matthew E Falagas ◽  
Rui Wang ◽  
Drosos E Karageorgopoulos ◽  
Xuhong Yu ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
Methicillin Resistant
Sign in / Sign up

Export Citation Format

Share Document